Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension safety study of JNJ-81201887 in geographic atrophy secondary to age-related macular degeneration
NL-OMON60274Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of JNJ-81201887 in geographic atrophy (GA) and age-related macular degeneration (AMD), sponsored by Janssen Pharmaceutical. Primary endpoints: Ocular and systemic treatment-emergent adverse events, Clinical laboratory and safety assessments and 1 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
JNJ-81201887
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON60274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60274.